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Abstract
Due to the particular structure and functionality of the placenta, most current human placenta drug testing
methods are limited to animal models, conventional cell testing, and cohort/controlled testing. Previous
studies have produced inconsistent results due to physiological differences between humans and animals and
limited availability of human and/or animal models for controlled testing. To overcome these challenges, a
placenta‐on‐a‐chip system is developed for studying the exchange of substances to and from the placenta.
Caffeine transport across the placental barrier is studied because caffeine is a xenobiotic widely consumed on
a daily basis. Since a fetus does not carry the enzymes that inactivate caffeine, when it crosses a placental
barrier, high caffeine intake may harm the fetus, so it is important to quantify the rate of caffeine transport
across the placenta. In this study, a caffeine concentration of 0.25 mg mL−1 is introduced into the maternal
channel, and the resulting changes are observed over a span of 7.5 h. A steady caffeine concentration of 0.1513
mg mL−1 is reached on the maternal side after 6.5 h, and a 0.0033 mg mL−1 concentration on the fetal side is
achieved after 5 h.
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1. Introduction
Caffeine is one of the most popular and 
widely consumed stimulants across the 
globe.[1] Coffee, tea, and cocoa are the pri-
mary natural sources of caffeine. Both 
health authorities and regulatory bodies 
have raised concerns about consumption 
of caffeine-enhanced food and beverages 
because of the increased availability of 
caffeine-enhanced food products containing 
synthetic caffeine.[2] Because caffeine is 
found not only in food and beverages, but 
also in prescription and over-the-counter 
medications, many pregnant women are 
very likely to consume caffeine in some 
form, so they may risk exposing underde-
veloped fetuses to this behaviorally active 
substance. There are concerns that overly 
heavy caffeine consumption may harm the 
fetus, since pregnant women require a half-
life 1.5 to 3.5 times greater to metabolize 
caffeine than non-pregnant women, pos-
sibly causing caffeine to remain in body 
tissues for longer periods of time. Caffeine has been found on 
locations within the fetal compartment, suggesting caffeine trans-
port across the placental barrier, and since a fetus would have 
difficulty in metabolizing caffeine due to lower levels of enzyme 
production in its developing liver, there is a real possibility that 
caffeine exposure could damage the fetus.[1,3] Because of unde-
termined effects from maternal caffeine intake on the fetus and 
the increased number of caffeine products available for pre-
natal consumption, health authorities such as the World Health 
Organization (WHO) and the Food and Drug Administration 
(FDA) have developed recommendations restricting caffeine 
intake during pregnancy and declaring caffeine consumption 
during pregnancy a global healthcare problem.[3–5]
Over the last decade, organ-on-a-chip technology has grown 
to become one of the most popular alternatives for drug testing 
and toxicology in vitro. Its aim is to create a 3D microenviron-
ment reminiscent of specific human organs as a means for rep-
licating their functionality.[6] The placenta has been one of the 
most difficult organs to replicate using organ-on-a-chip because 
it is a temporary organ that develops only during pregnancy and 
changes its structure and functionality over the course of the 
gestational period. To study this vital organ, in vivo, ex vivo, and 
Due to the particular structure and functionality of the placenta, most 
current human placenta drug testing methods are limited to animal 
models, conventional cell testing, and cohort/controlled testing. 
Previous studies have produced inconsistent results due to physiological 
differences between humans and animals and limited availability of 
human and/or animal models for controlled testing. To overcome these 
challenges, a placenta-on-a-chip system is developed for studying the 
exchange of substances to and from the placenta. Caffeine transport 
across the placental barrier is studied because caffeine is a xenobiotic 
widely consumed on a daily basis. Since a fetus does not carry the 
enzymes that inactivate caffeine, when it crosses a placental barrier, high 
caffeine intake may harm the fetus, so it is important to quantify the 
rate of caffeine transport across the placenta. In this study, a caffeine 
concentration of 0.25 mg mL−1 is introduced into the maternal channel, 
and the resulting changes are observed over a span of 7.5 h. A steady 
caffeine concentration of 0.1513 mg mL−1 is reached on the maternal 
side after 6.5 h, and a 0.0033 mg mL−1 concentration on the fetal side is 
achieved after 5 h.
Placenta-on-a-Chip
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Weinheim. This is an open access article under the terms of the Creative 
Commons Attribution License, which permits use, distribution and re-
production in any medium, provided the original work is properly cited.
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in vitro tests have been conducted. In vivo studies conducted 
on rats and baboons have yielded inconsistent results.[7–9] It is 
difficult to transfer the results from an animal testing model 
to a human model because placenta development is different 
in different mammals.[10–13] For example, in humans, glucose 
transport through the placental barrier is mediated by GLUT1 
glucose transporters, while in mice it is mediated by GLUT3 
transporters.[14] This difference shows why experiments using 
mice can yield lower glucose transfer rates than those found in 
similar experiments using human placentas. Previous studies 
have reported that in vitro microphysiological placenta systems 
are capable of exhibiting similar levels of glucose transport 
as those of actual placenta.[14,15] Moreover, in another study, 
the transport of two xenobiotic substances, heparin and gly-
buride, was studied using a bioengineered placental model, 
demonstrating the capability of a placenta-on-a-chip model to 
successfully mimic at least some of the physiological functions 
of the human placenta.[16] It has also been shown that these in 
vitro models are capable of mimicking placental inflammatory 
behavior from a placenta attacked with a bacterial infection.[17]
Even though humans are closely related to many other 
mammals, there is no yolk sac placentation in humans, and 
an allantoic stalk rather than an allantoic sac is present in a 
human placenta.[18] This makes it challenging to compare the 
results of experiments conducted on placentas of other mam-
mals to results of studies conducted on human placentas. Ex 
vivo studies in humans have also been conducted by obtaining 
placentas immediately after childbirth or cesarean sections.[19] 
These human studies only provide opportunities to study 
placentas and gain insight from women in their final term of 
pregnancy. Difficulty in obtaining consent from women for 
such participation in such studies and gaining access to pla-
centas before they become no longer viable makes these studies 
difficult to conduct. Moreover, ethical issues may limit experi-
mental research of this type, and observational studies may be 
difficult to perform because the women could be from a group 
self-selected for testing a particular drug.[20]
During pregnancy, both endogenous substances and xeno-
biotic substances consumed by a pregnant woman can pass 
through the placental barrier, possibly causing severe damage to 
a fetus either before or after birth. For example, an exogenous 
compound with the chemical nomenclature 1,3,7-Trimethylpu-
rine-2,6-dione, commonly known as caffeine, is quite often con-
sumed worldwide by pregnant women on a daily basis by way 
of ingesting coffee, tea, energy drinks, chocolate, etc., because 
it acts as a stimulant for the central nervous system (CNS).[20] 
Unfortunately, it has been found that such increased intake of 
caffeine by pregnant women can result in birth weight (BW) 
reduction in newborn children, or in reduced neonate size for 
its gestational age (SGA).[20–22] A meta-analysis of 32 studies 
suggests that caffeine intake is associated with an increased risk 
for reduction in BW, and another meta-analysis of 26 studies 
appeared to show a 43 g weight reduction in newborn children 
whose mothers appeared to be heavy caffeine consumers.[21,22] 
Despite these findings, it has never been recorded that caf-
feine directly causes BW reduction, also known as intrauterine 
growth retardation (IUGR).[23–28] While both meta-analyses 
exhibited some correlation with caffeine intake and BW, incon-
sistencies found in these studies suggest that there remains a 
need to identify a proper method for measuring exact caffeine 
levels crossing the placental barrier when a prospective mother 
consumes a certain amount of caffeine. Note that the effects on 
a fetus due to excessive intake of caffeine by pregnant women 
are beyond the scope of this study because it primarily focuses 
on the amount of caffeine infiltrating a placental barrier.
Caffeine is easily absorbed by the placental barrier and 
crosses the barrier freely.[23] Since the primary enzyme respon-
sible for caffeine metabolization, cytochrome P450 1A2, is 
absent both from the placenta and the fetus, the rate of metabo-
lism of caffeine depends totally on the metabolization capacity 
of pregnant women.[24] One study states that the half-life of 
caffeine has a range of 6–16 h in pregnant women compared 
to that for non-pregnant women, i.e., 2–8 h.[25,26] According to 
guidelines provided by the WHO and FDA, the intake of caf-
feine during pregnancy should not exceed 300 mg per day, 
making it necessary to measure a pregnant woman’s concentra-
tion of caffeine perfused into the fetus in relation to her total 
caffeine intake.[4,29]
Our placenta-on-a-chip device is designed to represent the 
trophoblastic epithelium and endothelium of the maternal 
interface and the fetal interface in a human placenta, respec-
tively. The chip was designed to carry two cell lines to represent 
both the maternal and the fetal sides. A porous membrane was 
placed between the two channels to serve as a barrier between 
the two bloodstreams. This membrane acts as an extracellular 
matrix (ECM) to provide support for surrounding cells used in 
our design. Human umbilical vein endothelial cells (HUVECs) 
and trophoblasts cells (BeWo) were respectively chosen to rep-
resent the endothelium in the fetal interface and the epithelium 
in the maternal interface. This work will enable us to establish 
a platform for studying the pharmacokinetics of different xeno-
biotic drugs across the placental barrier, and also enable us to 
examine the safety of drugs administered to pregnant women.
2. Results and Discussion
2.1. Cell Growth and Characterization on Membrane
The HUVECs and BeWo cocultured microfluidic device pro-
vided a relevant environment for representing the propagation 
of a human placenta. The human placenta in vivo consists of 
three main parts: the epithelium, the endothelium, and the pla-
cental barrier. As intended, we were able to replicate an in vivo–
like microsystem with HUVECs representing the endothelium, 
BeWo cells representing the epithelium, and a semiperme-
able membrane representing the placental barrier. CellTracker 
results (Figure 1a–d) showed a proliferation of cells over time 
and cell characterization was used to further study the forma-
tion of a placental barrier–like interface used to replicate and 
mimic placenta-related physiology. During medium perfu-
sion, cells were able to cover the entire area of both sides of 
the membrane within 24–30 h from the cell seeding. Cell adhe-
sion on the porous membrane is an important step in properly 
representing each cell line, and ECM macromolecules play an 
important role in proper growth and normal function of pri-
mary cells.[30] The most important cell-adhesion control variable 
was the cell adhesion time. Various time periods were tested 
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to identify the optimal time for cells to reach solid attachment. 
Another important parameter affecting cell viability on the 
channel was the flow rate. Since high flow rates produce high 
levels of shear stress on the channel walls, and can thereby 
force attached cells to detach from the membrane and flush 
out of the device, we tested different flow rates to seek the best 
results while also satisfying the previously discussed conditions. 
In the upper channel where BeWo cells were introduced, cells 
began forming a 3D structure and thereby affected long-term 
cell growth in the upper channel. As cell coverage increased, 
the space remaining for the medium to cross the channel 
had decreased, causing medium flow to exert pressure on the 
cells.
When fabricating a placental-barrier-like semipermeable mem-
brane, it is important to verify the formation of tight cell–cell 
junctions. E-cadherin is considered to be an important molecule 
when seeking to maintain cell–cell adhesion in the epithelial cell 
layer because it is restricted to regions of adherence junctions.[31] 
We used E-cadherin present on trophoblast cells to validate the 
formation of tight junctions and strong cell–cell adhesion in 
the epithelium. After 3 days, BeWo cells were stained with anti-
E-cadherin and scrutinized for red fluorescent protein (RFP). As 
shown in Figure 1e, BeWo cell–cell boundaries tested positive 
when stained for E-cadherin, verifying existence of tight junctions 
across the epithelial cell layer. Tight junctions in the endothelial cell 
layer ensure tissue integrity and play a vital role in maintenance 
Global Challenges 2019, 3, 1800112
Figure 1. Cells in channels after 48 h of media perfusion. a) BeWo cells with RFP grayscale imaging, b) BeWo cells with RFP color imaging, c) HUVECs 
with GFP grayscale imaging, d) HUVECs with GFP color imaging, e) BeWo cells showing epithelial adherence junctions with E-Cadherin and Nuclei 
labeled with DAPI staining, f) HUVECs showing endothelial adherence junctions with VE-Cadherin and Nuclei labeled with DAPI staining, scale 
50 microns and g) fluorescence intensity measured using dextran for 4 h, data represented as a fraction of maternal intensity/fetal intensity. n = 3 
independent experiments. Data are presented as mean (±SD).
www.advancedsciencenews.com
1800112 (4 of 9) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.global-challenges.com
and control of endothelial cell contacts.[32] VE-cadherin was used 
to investigate cell–cell interactions and the formation of tight junc-
tions on HUVECs that represent the endothelium. Similarly, after 
3 days of medium perfusion, HUVECs were marked with anti-
VE-cadherin and analyzed for green fluorescent protein (GFP). As 
shown in Figure 1f, VE-cadherin was detected on cell–cell parti-
tions, verifying the occurrence of tight junctions in the endothe-
lial cell layer. The E-cadherin and VE-cadherin-labeled cell–cell 
boundaries implied the formation of tight junctions and verified 
that both the epithelial and endothelial cell layers consisted of a 
confluent monolayer of cells on the membrane.
Placental barrier permeability was evaluated using 3000 MW 
fluorescein–dextran anionic probes. When dextran was intro-
duced to the maternal side, fluorescence intensities on both 
the maternal side and the fetal side were recorded, and the data 
represented as a fraction, with maternal intensity the numer-
ator and fetal intensity the denominator, as shown in Figure 1g. 
We observed that, while maternal fluorescence increased over 
time due to the dilution of the dextran-mixed medium by the 
remaining medium in the channels and by the tubing, fetal 
fluorescence intensity remained at a lower level. Even though 
a few molecules were diffused from the maternal side to the 
fetal side across the membrane, overall fetal intensity remained 
insignificant over time, verifying the integrity of the placental-
barrier-like semipermeable membrane.
2.2. Quantitative Analysis of Caffeine Transport
2.2.1. Concentration of Caffeine Transported through Placental Barrier
Before calculating caffeine concentrations, we plotted the data 
obtained from the area under the curve for each chromatogram 
with respect to time, as shown in Figure 2, and the fetal side 
(Figure 2a) of the control (samples collected from a chip con-
sisting of a bare membrane with perfusing EGM and F-12K) 
showed more fluctuation in terms of the number of counts 
(representing the area) with a positive gradient with respect to 
time up to t = 6.5 h. Between t = 6.5 h and t = 7.5 h, concentra-
tions (represented by the number of counts) sought to reach 
a steady-state while achieving a peak-level of caffeine diffusion 
through the placental barrier. Conversely, the actual data (from 
chips with cells and medium) show less data variability, with a 
positive gradient, but data remained in a lower range than in 
the controlled tests. The actual data also exhibited reaching a 
peak diffusion between t = 5 h and t = 7.5 h. On the maternal 
side (Figure 2b), control data always remained lower than 
actual data, but it exhibited greater fluctuation than the actual 
data while the system was moving toward its optimum diffu-
sion stage, and this trend was also observed on the fetal side. 
The data show attainment of steady-state between 6 and 7.5 h 
for actual data.
Using data obtained from both the maternal and fetal 
calibration curves, individual quadratic curves were fitted 
and equations with a 95% confidence level found for them. 
Equations (1) and (2) represent curves fitted for EGM (fetal) 
and F-12K (maternal), respectively.
A e C e C e= − + +8.06 5.80 3.46f
8
f
2 8
f
5
 (1)
A e C e C e= − + +2.04 3.97 4.64m
8
m
2 8
m
6
 (2)
where A and C represent the area under the curve from the 
liquid chromatography mass spectrometry (LCMS) method 
and the calculated caffeine concentration, respectively. Roots 
were obtained from each equation for both maternal and fetal 
Global Challenges 2019, 3, 1800112
Figure 2. Area under the curve for each chromatogram from LCMS, which were generated for each sample collected from both the maternal and fetal 
outlet after every 30 min. a) Chromatogram area output for EGM (fetal side). b) Chromatogram area output for F-12K (maternal side). Actual tests 
have both cells in the chip and the control has just the bare membrane with media perfusing through the channels. n = 3 independent experiments. 
Data are presented as mean (±SD).
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caffeine transport. We neglected one root under the condition: 
C ≤ 0.25 mg mL−1 because the highest caffeine concentration 
introduced was 0.25 mg mL−1 on the maternal side.
Figure 3a,b shows calculated concentrations with respect 
to time that followed the same trend as in Figure 2. Examina-
tion of caffeine concentrations for actual tests on the fetal side 
(Figure 3a) reveals a more conclusive result than that for con-
centrations represented by areas under the curve (Figure 2a). In 
this study, we investigated both the steady-state concentration 
and with the amount of time required to reach this condition. 
Knowing steady-state concentrations on the maternal and fetal 
sides will assist in verifying the safest dose of caffeine to be 
taken by a mother when a certain concentration is described 
in terms of the safe concentration level in the fetus. Since this 
system was used only as a proof-of-concept to verify the caffeine 
transport across the placenta in vitro, only one caffeine con-
centration (0.25 mg mL−1) within the safe amount of caffeine 
according to FDA was tested. After 5 h, the caffeine concen-
tration began to reach a steady-state of 0.0032 mg mL−1, and 
between 5 and 7.5 h, it maintained an average of 0.0033 mg mL−1 
in steady-state. Fetal caffeine concentration in controlled tests 
reached its peak at t = 6.5 h, and between 6.5 and 7.5 h it 
achieved its steady-state at an average of 0.0179 mg mL−1. Simi-
larly, analyzing the caffeine on the maternal side (Figure 3b) 
shows that steady-state for the actual tests was achieved 
between 6 and 7.5 h at a value of 0.1513 mg mL−1 (average). 
Global Challenges 2019, 3, 1800112
Figure 3. Caffeine concentrations calculated for both the maternal and fetal sides. a) EGM (fetal side). b) F-12K (maternal side). Actual tests have both 
HUVECs and BeWo cells on the chip and the control has solely the bare membrane with media perfusing through the channels. c) Calibration curve 
for caffeine concentrations in EGM (concentrations ranging from 0.00001 to 0.25 mg mL−1). d) Calibration curve for caffeine concentrations in F-12K 
(concentrations ranging from 0.05 to 0.3 mg mL−1). n = 3 independent experiments. Data were presented as mean (±SD).
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During the controlled experiment, it was noted that steady-state 
was achieved after 7 h at a caffeine concentration of 0.1307 mg 
mL−1. After 7.5 h, we observed cells detaching from the mem-
brane. At this point, we concluded that the system could no 
longer provide a confluent layer of cells and would therefore 
not adequately represent a system to be used for actual experi-
ments. Such failure could be attributed either to effects of caf-
feine on the cells or flow phenomenon inside the channels. 
Further studies are required to identify or confirm reasons 
for underlying cell detachment. Steady-state was defined at 
the point in time or time range where caffeine concentrations 
seemed to maintain a steady value with respect to time while 
caffeine continued to be introduced into the maternal side at a 
constant flow rate.
A study on a physiologically based human model of a 
pregnant woman concluded that, after introducing caf-
feine, the concentration increased until it reached a steady-
state value.[33] In that study, multiple doses were introduced, 
and each time the peak concentration was increased until 
it reached a steady-state condition. We introduced about 
0.0938 mg of caffeine to the maternal side within 7.5 h 
through medium perfusion, and while we can relate our tests 
to a similar study using multiple doses over time, the doses 
were continuously given, possibly explaining why Figure 2a,b 
has multiple peaks but only reached a single steady-state 
condition. Since we continuously perfused caffeine diluted 
medium for 7.5 h, continuous perfusion resulted in multiple 
peaks with only a single steady-state region. In addition, con-
centrations reported in controlled experiments were signifi-
cant in the absence of caffeine on either the maternal side or 
the fetal side because caffeine that perfused to the maternal 
side should come from either the maternal side or the fetal 
side; we believe this is due to caffeine absorption to the edges 
on poly(dimethylsiloxane) (PDMS) side walls in the maternal 
channel. This was not significantly observed in actual experi-
ments due to the cell coverage in channels.
While the collected volume might have only a minimal error, 
even this small error could affect the final calculated value. For 
example, while the expected volume within a 30 min perfusion 
period is 25 µL (with a flow rate of 50 µL h−1), only a small error 
in volume could dilute the medium with an incorrect volume of 
methanol. This error was minimized by measuring the volume 
of the sample collected during each 30 min period diluted with 
the correct amount of methanol. In Figure 2a, the number of 
counts measured at later time points (i.e., t = 6 h) at the fetal 
side showed the same standard deviation order value as the 
average. This was observed at early time points (i.e., t = 2 h) 
on the maternal side, as shown in Figure 2b. Fluctuations of 
caffeine concentrations on the both maternal and fetal sides at 
later time points could be attributed to cell detachment, but ear-
lier fluctuation of the maternal concentration could be a result 
of different medium dilutions with methanol, as mentioned 
earlier. Further studies are needed to find specific reasons for 
these errors. In Figure 3b, it was noted that the highest calcu-
lated caffeine concentration (0.2591 mg mL−1) was detected at 
t = 1.5 h. While this value is greater than the caffeine concen-
tration introduced to the maternal side (0.25 mg mL−1), during 
the calculation process the fitted curves (in Figure 3c,d) were 
made with a 95% confidence level and that error could affect 
the caffeine concentrations calculated on both maternal and 
fetal sides.
2.2.2. Rate Transfer of Caffeine
The rate of caffeine transfer was calculated for both maternal 
and fetal sides using the following equation (Equation (3)):
RT
C
C
=
Δ
Δ
×% 100f
m
 (3)
where ΔCf and ΔCm represent the change in caffeine con-
centrations in the fetal and maternal channels, respectively, 
during perfusion. Initial and final caffeine concentrations 
from both the maternal and fetal sides were used when cal-
culating the values for ΔCf and ΔCm. To calculate the initial 
maternal and fetal caffeine concentrations, the values at a 
previous time point were used for both the actual and con-
trolled experiments (Figure 4). Calculated rates were used to 
measure the change in rate of caffeine transfer with respect 
to the rate of caffeine transfer calculated at the previous 
time point (i.e., if the rate of caffeine transfer was calcu-
lated at t = 5 h, the values at t = 4.5 h were used as the initial 
concentrations).
As shown in Figure 4, the transfer rates for actual tests (with 
cells) reflected less fluctuation when compared to the rate 
calculated for controlled tests (without cells), when more caf-
feine was introduced into the system. In actual experiments, 
the transfer rates calculated from t = 1 h to t = 3 h show a 
Global Challenges 2019, 3, 1800112
Figure 4. The rate of caffeine transfer calculated at every 30 min for both 
the actual (with cells) and control (without cells) tests. The rates were 
calculated cumulatively using the values at previous time point as the 
initial-maternal and initial-fetal concentrations (i.e., if the rate of transfer 
is calculated at t = 6 h, values at t = 5.5 h were used as the initial-maternal 
and initial-fetal concentrations). n = 3 independent experiments. Data 
were presented as mean (±SD).
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gradual decrease, followed by a sudden increase and another 
gradual decrease in caffeine transfer rate observed between 
t = 3 h and t = 5 h. Similar patterns were seen in transfer 
rates for the controlled tests from t = 1.5 h to t = 4 h. The 
frequent fluctuations were attributed to the constant perfusion 
of caffeine at 50 µL h−1 to the maternal side, although fur-
ther investigation is needed to find the exact reasons for such 
fluctuations. It has been previously reported that the transfer 
rate of caffeine across a placental barrier depends also on its 
physiochemical properties such as its size (molecular weight), 
ionization yield, lipophilicity (Log P), and protein binding.[34] 
High-permeability coefficients are observed for small polar 
molecules because such compounds pass readily through lipid 
membranes.[35]
Assertions about the amount of caffeine safe for consump-
tion during pregnancy vary depending on the study referenced, 
and the FDA, taking into account for all the variations for this 
value has stated that any amount less than 300 mg per day is 
safe for pregnant women.[29] In our study, we used a concentra-
tion of 0.25 mg mL−1 of caffeine, less than the FDA-specified 
amount (300 mg per day = 0.67 mg mL−1), for perfusion 
analysis.
3. Conclusions
In this study, we successfully fabricated a placenta-on-a-chip 
device using PDMS soft lithography techniques. After con-
firming that we had a confluent layer of cells, we used it to 
conduct caffeine transport analysis. A caffeine calibration curve 
was initially established to quantify the caffeine in collected 
media from both maternal and fetal channels. Using an inte-
grated equation, caffeine concentrations in each media were 
calculated for each sample over a 7.5 h time span, producing 
a result showing that caffeine concentration on the fetal side 
increases until it reaches a steady-state condition. In actual tests 
(with cells), caffeine concentration on the fetal side reached a 
steady-state of 0.0033 mg mL−1, while in controlled tests it 
reached the steady-state of 0.0179 mg mL−1 in the interval 
between 6.5 and 7.5 h. On the maternal side, while initial 
Global Challenges 2019, 3, 1800112
Figure 5. The placenta-on-a-chip consists of two layers of PDMS separated with a porous membrane and channel on each side. a) Top and 
bottom layers with a porous membrane separating the channels before being attached. b) Channels aligned and ready to be attached and the 
porous membrane placed in between the layers to separate the midsections of each channel (where two cell layers interact). c) Cross-sectional 
view of the channels. d) Experimental concept that shows the maternal and fetal bloodstreams perfused through the channels (not 
to scale).
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concentrations fluctuated, they reached steady-state within 
7.5 h. The steady-state value was 0.1513 mg mL−1 between 6.5 
and 7.5 h for the actual tests and 0.1307 mg mL−1 after 7 h for 
the controlled tests. This result clearly warrants further inves-
tigation on perfusing different caffeine concentrations to the 
maternal interface and the way they affect transfer rates.
4. Experimental Section
Cell Culture: HUVECs (Lonza) were chosen to represent the cells 
at the fetal interface. The cells were cultured with endothelial basal 
medium (EBM, R&D Systems), supplemented with Endothelial cell 
growth supplement (R&D Systems) containing fetal bovine serum 
(FBS). BeWo (ATCC) was selected from a variety of trophoblast cell 
lines based on its adhesive properties, functionality, and phenotype.[36] 
BeWo was used to represent the cells at the maternal interface. The 
cells were cultured in Kaighn’s Modification of Ham’s F-12K medium 
(Thermofisher), supplemented with 10% FBS (Thermofisher). Both cell 
lines were maintained in an incubator at 37 °C with 5% CO2 in air until 
they were 80–90% confluent.
Design and Fabrication of the Chip: The placenta-on-a-chip device 
(Figure 5) consisted of two microchannels (height: 100 microns; width: 
400 microns) fabricated on two PDMS layers. An SU-8 mold for the chip 
was created using standard soft lithography techniques. The silicon wafer 
mold was placed in a 15 cm diameter petri dish, and then a 10:1 w/w 
mixture of PDMS base and curing agent solution (Dow Corning) were 
introduced into the mold.[37,38] Once the PDMS had solidified at room 
temperature, it was cut and peeled away from the mold to separate it 
into upper and lower layers. To provide fluid access for each individual 
channel, inlet/outlet holes (1 mm diameter) were created using a biopsy 
punch. A 0.4 micron pore-sized polyester track etched (PETE) membrane 
from the membrane inserts (Corning) was used to represent the barrier 
between fetal and maternal bloodstreams. The membrane covered the 
mid-section of the lower channel before both layers were treated with 
plasma for 1 min, and the two PDMS layers were then aligned, attached, 
and left overnight to perfectly cure the bond. 1/16 ft diameter PEEK tubes 
(IDEX Health and Science) were then inserted into the inlets and outlets, 
attached to 0.062 × 0.125 in laboratory tubing (DOW Corning), then left 
overnight before use. After the layers were permanently bonded, the 
chip was UV-sterilized for 20 min. Entactin–collagen IV–laminin (E–C–L, 
Millipore) solution was prepared from a diluted solution of E–C–L with 
a sterile serum-free medium for each cell line up to a final concentration 
of 10 µg mL−1. Both sides of the membrane were initially coated with 
E–C–L solution, after which the chips were refrigerated overnight at 4 °C. 
Prior to cell seeding, the channels were washed twice with phosphate-
buffered saline (PBS) to remove excess E–C–L.
Microfluidic Cell Seeding and Culturing on the Chip: Once the HUVECs 
and BeWo cells reached 80–90% confluence, the cells were prepared for 
infusion. The density of the dissociated cells was adjusted to 5 × 106 
cells mL−1. The HUVECs were suspended in EGM medium, seeded into 
the lower channel, and incubated in an inverted position at 37 °C with 
5% CO2 in air for 1 h to ensure reliable attachment to the membrane. 
Similarly, the BeWo cells suspended in F-12K medium were introduced 
into the upper channel and incubated at the original position under 
similar conditions for 1 h. Once cell attachment was confirmed, the inlet 
of each channel was connected to 3 mL syringes (Becton, Dickinson 
and Company) filled with the respective growth media for each cell type 
seeded into the channels, after which the syringes were connected to a 
syringe pump driven at a constant volumetric flow rate of 50 µL h−1.
Observing Live Cells: The HUVECs and BeWo cells were stained 
with CellTracker green and CellTracker orange fluorescent probes 
(Life Technologies), respectively. Dissociated cells were incubated with 
staining diluted serum-free medium (final working concentration of 
0.5–25 × 10−6 m) at 37 °C with 5% CO2 for 45 min.
Investigating the Barrier Permeability: Three thousand megawatt 
fluorescein–dextran anionic probes (Invitrogen, ThermoFisher) were 
used to measure the barrier permeability function based on its transport 
between maternal and fetal channels. Fluorescein–dextran was first 
diluted in PBS to 100 mg mL−1 then brought to a final concentration 
of 0.1 mg mL−1 in F-12K medium. F-12K supplement for the maternal 
channel was replaced with dextran-mixed F-12K and perfused for 4 h. 
Flow from both maternal and fetal channels was collected each hour and 
the fluorescence intensity of the collected samples was analyzed using a 
microplate reader (BioTek Synergy 2).
Cell Characterization for Analyzing Intercellular Junctions: After 
confirming proliferation of cells on membranes inside the channels for 
a minimum of 3 days, the channels were rinsed twice with 0.1 m PO4 
buffer, after which the cells were fixed in 4% paraformaldehyde and 
incubated at room temperature for 20 min. The channels were then 
washed thrice with PBS at 7 min increments. The channels were 
subsequently incubated at room temperature in a blocking solution 
created using 5% normal donkey serum as the normal blocking serum 
(NBS, Jackson Immuno Research Labs), 0.4% bovine serum albumin 
(BSA), and 0.2% Triton X-100 for 60 min. Following incubation, primary 
antibodies (E-cadherin and VE-cadherin [Cell Signaling Technologies] for 
BeWo and HUVECs, respectively) were diluted in previously prepared 
blocking serum and incubated in each channel overnight at 4 °C. After 
being washed in PBS 4 times, the channels were incubated for 90 min 
with secondary antibodies and DAPI solution diluted in the same 
blocking solution. The channels were then rinsed with PBS 4 times 
with 8 min intervals between each rinse. After carefully separating the 
membrane from the chip, it was mounted to a coverslip and imaged 
with an inverted microscope (Zeiss Axio Observer Z1).
Analysis of Caffeine Transport: An LC/MS analytical method was used 
to determine the caffeine concentrations, using an Agilent Technologies 
1100 Series advanced high-performance liquid chromatography (HPLC) 
tandem mass spectrometer equipped with a Poroshell 120 EC-C18 
2.7 µm 4.6 mm × 50 mm (Agilent) column (W.M. Keck Metabolomics 
Laboratory, Iowa State University), to detect caffeine levels.[39] This 
instrument is composed of a UV–vis capable diode array detector and 
an Agilent Technologies Mass Selective Trap SL detector equipped with 
an electrospray ion source.
To prepare the collected samples for runs, each sample was diluted 
at a ratio of 1:3 in methanol and vortexed for several seconds, after 
which the samples were centrifuged at 16 × g for 5 min and 100 µL 
from each sample was transferred to separate vials. The mobile phase 
was a mixture of water (80% with 0.1% acetic acid) and acetonitrile 
(20% with 0.1% acetic acid). The mass analyzer operated with an ESI 
source in positive ion mode, and the flow rate and injection volume were 
0.75 mL min−1 and 5 µL, respectively. The quantification for caffeine was 
determined by measuring the intensity of protonated molecular ions of 
caffeine at m/z 195.
Caffeine Transport across the Placental Barrier: Calibration curves were 
initially developed so that the correlation could be used to calculate 
the amount of caffeine transported from the maternal side to the fetal 
side. Different caffeine (Sigma Aldrich) concentrations ranging from 
0.00001 to 0.25 mg mL−1 in EGM and from 0.05 to 0.3 mg mL−1 in 
F-12K were used to create calibration curves using the data collected 
via the LCMS method. Assuming that the area under the curve for the 
caffeine spike from chromatogram (example chromatogram as shown 
in Figures S1 and S2 in the Supporting Information) was proportional 
to the concentration of the caffeine in each medium, the two different 
graphs shown in Figure 3c,d were used to represent the correlation 
between concentration of caffeine and area under the curve. A 0.25 mg 
mL−1 caffeine solution in F-12K medium was then introduced into the 
maternal side. Following a 1 h perfusion period, samples were collected 
after every 30 min from both the maternal and fetal outlets, and each 
sample was analyzed using the LCMS method to identify the exact 
amount of caffeine transported across the placental barrier.
Quantification of Caffeine Concentrations and Transfer Rates: Using 
Figure 3c,d, the caffeine concentrations for both the maternal and fetal 
sides were quantified and used to study the percentage increase of 
caffeine concentration in the fetal compartment over a period of medium 
perfusion. Equation (3) was used to calculate the rate of caffeine transfer.
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